A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer

A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer is a phase 2, interventional study registered as NCT07347951 by First Affiliated Hospital of Wenzhou Medical University, with a registry enrolment figure of 30 participants, started 2025-12-01 and due to reach its primary completion in 2027-12-01. Interventions recorded: Short-course radiotherapy; CAPOX chemotherapy; Targeted therapy with bevacizumab; Serplulimab immunotherapy. Conditions listed: Locally Advanced Rectal Cancer (LARC). Primary outcome: Pathological complete response (pCR) rate. Colorectal eligibility wording from the registry: "* Diagnosed via pelvic MRI and rectoscopy with a tumor located ≤10 cm from the anal verge, with a clinical stage of cT3-4N0/+M0, and lymph nodes confined within the mesorectum". Sites: China. No results are recorded here; the registry entry is the source.